Search This Blog

Friday, January 10, 2020

LogicBio Therapeutics collaborates with Takeda for LB-301

LogicBio Therapeutics (NASDAQ:LOGCannounces a research collaboration with Takeda Pharmaceutical (OTCPK:TKPHF) to further develop LB-301 for the treatment of Crigler-Najjar syndrome.
Under the agreement, Takeda will provide funding for the research program and will have an exclusive option to negotiate an exclusive, worldwide license to LogicBio’s LB-301 program.
LB-301 is a recombinant adeno-associated viral vector with a uridine disphosphate-glucuronosyltransferase-1 gene leveraging GeneRide genome editing platform for the treatment of Crigler-Najjar syndrome.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.